Skip Main Navigation
Page Content

Save This Event

Event Saved

Science First: An Era of Oncolytic Virus Immunotherapy

JLABS San Diego

Thursday, March 15, 2018 from 3:00 PM to 6:00 PM (PDT)

Science First: An Era of Oncolytic Virus Immunotherapy

Registration Information

Registration Type Sales End Price Fee Quantity
General Public Mar 14, 2018 $35.00 $4.01
Student Mar 14, 2018 $25.00 $3.45
Press Mar 8, 2018 Free $0.00
At the door Mar 15, 2018 $45.00 $4.56

Share Science First: An Era of Oncolytic Virus Immunotherapy

Event Details

The use of viruses to kill cancer has been recognized for many years, but the more recent immunotherapeutic approach has sparked a wave of innovation in oncolytic virus-based drug development. With progress in areas like genetic engineering and an advanced understanding of viral genes, oncolytic virus therapy could be the next major breakthrough in cancer treatment.

Join Johnson & Johnson Innovation, JLABS as we bring together three innovators advancing oncolytic virus-based therapies that are currently in the clinic. Hear from entrepreneurs on the front lines developing cutting-edge solutions – including ones that utilize a common respiratory virus for good! These scientific experts will share their data and insights to advance our understanding of this fascinating space, and the unique challenges they face in the race to gain drug approval.

We'll explore topics such as:

  • Next generation approaches to oncolytic virus therapeutics
  • Challenges in drug development
  • Clinical trial design
  • Regulatory and commercialization pathways
  • Biosafety concerns

Presenting Companies:
DNAtrix read bio»
EpicentRX read bio»
More companies coming soon!

3:00pm | Registration and networking
3:25pm | Introduction
3:35pm | Presentations
4:20pm | Panel Discussion and Q&A
5:15pm | Networking Reception*
6:00pm | Program Close
*Hors d’oeuvres and beverages provided

$35 | General Public
$25 | Student
$45 | At the Door

JLABS in San Diego
3210 Merryfield Row
San Diego, CA

About the Science First series:
The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings together top experts to explore pressing topics in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.

Presenting Company Descriptions:
DNAtrix is a privately held biotech company focusing on the development of oncolytic viruses for cancer. The company’s initial focus is on glioblastoma, a devastating brain tumor that is currently incurable. Since viruses are already good at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. More than 35 patients have been treated with the cancer-killing virus, called DNX-2401, with excellent early results. Company’s lead product, DNX-2401, is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications.

EpicentRx, a clinical stage biotechnology company, is at the forefront of the rapidly emerging field of epigenetics and has the potential to change the face of medicine. With a focus on the epicenter of life science innovation and forward-thinking leadership, EpicentRx embodies a “radical” new approach to discover and develop improved therapeutic options from non-traditional sources for unmet medical needs.

More coming soon!

Have questions about Science First: An Era of Oncolytic Virus Immunotherapy? Contact JLABS San Diego

Save This Event

Event Saved

When & Where

3210 Merryfield Row
San Diego, California

Thursday, March 15, 2018 from 3:00 PM to 6:00 PM (PDT)

  Add to my calendar


JLABS San Diego

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to eight locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto and a ninth location, New York City, launching in 2018. For more information please visit

  Contact the Organizer
Science First: An Era of Oncolytic Virus Immunotherapy
Things to do in San Diego Networking Business

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.